Abstract
With the growth of clinical Positron Emission Tomography (PET) utilizations, new molecular tracers, able to aid in the assessment, therapy planning and monitoring of cancer patients, are synthesized. As suggested by some works reported in the literature, these newcomers may be positron emitting isotopes of lanthanium, 134La, iodine, 120I, 121I and 124I, arsenic, 72As and 74As, oxygen, 14O, and neon, 19Ne. In this work, we present an inter comparison of these eight radiopharmaceuticals which may be used in PET. To do that we have used a Monte Carlo simulation of positron following-up in water that we have adapted to the beta decay of radionuclides. We have also access to accurate spatial and energetic distributions of the potential PET radiopharmaceuticals under investigation here. The results are given in an analytical way and have been compared, when possible, with theoretical and experimental values available in the literature.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.